Abstract | PURPOSE OF REVIEW: RECENT FINDINGS: SUMMARY: In a multicenter phase-2 randomized controlled study in the European Union, the efficacy and safety of gantacurium were evaluated, but results have not yet been published. Sugammadex is currently available in the European Union, but the United States Food and Drug Administration has had concerns about its safety ( hypersensitivity and allergic reactions) and has asked for additional safety data. It is hoped that the widespread use of sugammadex in the European Union will provide additional information.
|
Authors | Mohamed Naguib, Sorin J Brull |
Journal | Current opinion in anaesthesiology
(Curr Opin Anaesthesiol)
Vol. 22
Issue 4
Pg. 483-90
(Aug 2009)
ISSN: 1473-6500 [Electronic] United States |
PMID | 19384229
(Publication Type: Journal Article, Review)
|
Chemical References |
- CW 002
- Cholinesterase Inhibitors
- Isoquinolines
- Neuromuscular Nondepolarizing Agents
- gamma-Cyclodextrins
- Sugammadex
- Cysteine
- gantacurium
|
Topics |
- Animals
- Cholinesterase Inhibitors
(pharmacology)
- Cysteine
(metabolism, pharmacology)
- Humans
- Isoquinolines
(pharmacology)
- Neuromuscular Nondepolarizing Agents
(pharmacology)
- Sugammadex
- gamma-Cyclodextrins
(pharmacokinetics, pharmacology)
|